[Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone].
Seven patients who had been receiving capecitabine+oxaliplatin±bevacizumab(CapeOX±BV)therapy at our hospital between February 2010 and March 2011, had complained of angialgia during oxaliplatin(L-OHP)administration. Therefore, 3. 3 mg of dexamethasone(DEX)was added to their infusion solution. The patients were then asked to rate their angialgia severity using a numerical rating scale(NRS), when L-OHP in a 5% dextrose solution was administered with or without DEX. By changing the L-OHP in 5% dextrose solution without DEX to the solution containing 3. 3 mg of DEX, the mean NRS was improved to 2. 4 from 7. 1. These findings indicate that L-OHP in 5% dextrose solution mixed with 3. 3 mg of DEX seems to be useful in reducing angialgia during peripheral administration of L-OHP.
Dept. of Pharmacy, Yatsushiro Social Insurance General Hospital, Japan.
Yuki
Y
Shiotsuka
Miki
M
Uebuchi
Seiji
S
Hamada
Naofumi
N
Morita
Akira
A
Moriyama
Mayuko
M
Yamashita
Yasuko
Y
Ichikawa
Hiroshi
H
Fujii
Akinobu
A
Matsuo
Hiroshi
H
Kuhara
Yoshiaki
Y
Ikuta
Satoshi
S
Ikeshima
Masafumi
M
Kuramoto
Kenichiro
K
Fujii
Shinya
S
Shimada
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000601:surgery; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003907:Dexamethasone